- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05795010
MRD Test in Common Risk Stage II Colorectal Cancer (HuaMC-1)
March 29, 2023 updated by: First Affiliated Hospital Xi'an Jiaotong University
Observation of MRD Detection for Preoperative Sensitivity and Postoperative Positive Rate in Common Risk Stage II Colorectal Cancer
Patients with colorectal cancer who were confirmed as stage II general risk type in the postoperative pathological report began to be enrolled.
Observe the sensitivity of the detection of micro-MRD before operation and the postoperative positive rate of this type of patients.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This observation part is about the patients with general risk stage II colorectal cancer who have received R0 resection after screening by nanofiltration criteria.
Twenty milliliters of venous blood samples were reserved before surgery, and tumor tissue samples were reserved within 30 minutes in vitro during surgery.
After the pathological diagnosis of the patients after surgery, they began to be enrolled.
To observe the sensitivity of MRD detection in preoperative diagnosis of patients with general risk stage II colorectal cancer, and to study its positive rate one month and three months after operation.
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yongchun Song, MD
- Phone Number: 0086-18991232549
- Email: 758327495@qq.com
Study Contact Backup
- Name: Gang Xu, MD
- Phone Number: 0086-15829030108
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- First Affiliated Hospital of Xian Jiaotong University
-
Contact:
- Yongchun Song, MD
- Phone Number: 0086-18991232549
- Email: 758327495@qq.com
-
Contact:
- Gang Xu, MD
- Phone Number: 0086-15829030108
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Preoperative venous blood and intraoperative tumor tissue samples were reserved for patients with colorectal cancer who were estimated as stage II general risk type by pelvic magnetic resonance imaging.
Patients with colorectal cancer who were confirmed as stage II general risk type in the postoperative pathological report began to be enrolled
Description
Inclusion Criteria:
- Age 18-75;
- Pathologically confirmed rectal adenocarcinoma;
- Pathological differentiation is highly or moderately differentiated;
- The pathological stage was pT3N0, that is, invasion of the proper muscular layer of the intestinal wall without lymph node metastasis;
- No new adjuvant treatment before operation
- There was no vascular infiltration and nerve infiltration in postoperative pathology;
- No preoperative intestinal obstruction or tumor site perforation;
- No postoperative pathological margin was positive or unknown;
- The distance between the pathological cutting edge and the tumor was more than 1 cm;
- Invasion of mesentery of intestinal wall ≤ 2mm;
- More than 12 lymph nodes were submitted for examination;
- Nonlocal recurrence and distant metastasis;
- No multiple primary carcinoma of colon and rectum;
- Physical condition score PS ≤ 2 points;
- Patients and their families can understand and are willing to participate in this study and provide written informed consent.
Exclusion Criteria:
- Multiple intestinal carcinomatosis
- Previous history of malignant tumor,
- There are concurrent malignant tumors in the whole body except for colorectal cancer
- Colorectal cancer with preoperative anti-tumor treatment
- Pregnant or lactating women
- There are serious complications during or after operation, affecting the prognosis
- Hepatitis B or Hepatitis C antibody positive
- HIV antibody positive
- Other diseases considered by the research doctor to affect the prognosis and survival
- Other conditions that the research doctor believes are not consistent with this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive rate of preoperative MRD test
Time Frame: six months
|
To observe the positive rate of preoperative MRD detection for stage II colorectal cancer
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive rate of MRD test 1 month and 3 months after operation
Time Frame: nine months
|
Observe the positive rate of MRD detection at 1 month and 3 months after operation for stage II colorectal cancer
|
nine months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Yongchun Song, MD, First Affiliated Hospital of Xian Jiaotong University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjot L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528. Erratum In: JAMA Oncol. 2019 Jun 13;:
- Romero D. ctDNA guides omission of adjuvant chemotherapy for stage II CRC. Nat Rev Clin Oncol. 2022 Aug;19(8):493. doi: 10.1038/s41571-022-00657-7. No abstract available.
- Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, Khattak A, Burge M, Harris M, Lynam J, Nott L, Day F, Hayes T, McLachlan SA, Lee B, Ptak J, Silliman N, Dobbyn L, Popoli M, Hruban R, Lennon AM, Papadopoulos N, Kinzler KW, Vogelstein B, Tomasetti C, Gibbs P; DYNAMIC Investigators. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022 Jun 16;386(24):2261-2272. doi: 10.1056/NEJMoa2200075. Epub 2022 Jun 4.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 30, 2023
Primary Completion (Anticipated)
April 10, 2023
Study Completion (Anticipated)
September 30, 2023
Study Registration Dates
First Submitted
March 7, 2023
First Submitted That Met QC Criteria
March 29, 2023
First Posted (Actual)
April 3, 2023
Study Record Updates
Last Update Posted (Actual)
April 3, 2023
Last Update Submitted That Met QC Criteria
March 29, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XJTU1AF2023LSK-174
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Individual participant data will be published anonymously after the end of the study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage II Colorectal Cancer
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingGynecologic Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage III Breast Cancer | Stage III Gynecologic Cancer | Stage III Colorectal Cancer | Stage I Colorectal Cancer | Stage II Colorectal Cancer | Stage I Gynecologic... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of California, San FranciscoBristol-Myers Squibb FoundationCompletedStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Neoplasm | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal... and other conditionsUnited States
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Colorectal Cancer | Prostate Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage III Breast Cancer | Stage III Colorectal Cancer | Stage I Colorectal Cancer | Stage II Colorectal CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
Clinical Trials on MRD test
-
University of Texas Southwestern Medical CenterNot yet recruitingMuscle Invasive Bladder Cancer
-
Cancer Institute and Hospital, Chinese Academy...Beijing Huanxing Cancer Hospital; Cancer Hospital, Chinese Academy of Medical...RecruitingEarly-stage Breast CancerChina
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)CompletedParkinson DiseaseUnited States
-
Northern Italy Leukemia GroupAssociazione Italiana per la Ricerca sul CancroCompleted
-
Exact Sciences CorporationNSABP Foundation IncRecruitingColorectal CancerUnited States
-
WeiWei XiaoHaplox Biotechnology Co., Ltd.RecruitingMinimal Residual Disease | Circulating Tumor DNA | Rectal Adenocarcinoma | Neoadjuvant ChemoradiotherapyChina
-
BAIYONG SHENGeneCast Biotechnology Co., Ltd.Not yet recruitingPancreatic Cancer ResectableChina
-
University of ZurichCompletedIncontinence | AnismusSwitzerland
-
The First Hospital of Jilin UniversityGeneplus-Beijing Co. Ltd.Recruiting
-
Rajshekhar Chakraborty, MDHope FoundationRecruiting